279 related articles for article (PubMed ID: 25394901)
1. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
He X; Xiao X; Dong L; Wan N; Zhou Z; Deng H; Zhang X
Tumour Biol; 2015 Mar; 36(3):2065-75. PubMed ID: 25394901
[TBL] [Abstract][Full Text] [Related]
2. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
3. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
4. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
5. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
Wang X; Zhu J
Thorac Cancer; 2018 Jun; 9(6):676-683. PubMed ID: 29697201
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
7. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer.
Li M; Chen W; Zhang H; Zhang Y; Ke F; Wu X; Zhang Y; Weng M; Liu Y; Gong W
Oncotarget; 2016 Dec; 7(50):83060-83070. PubMed ID: 27825112
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
9. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O
Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276
[TBL] [Abstract][Full Text] [Related]
10. miRNA-106a Promotes Breast Cancer Cell Proliferation, Clonogenicity, Migration, and Invasion Through Inhibiting Apoptosis and Chemosensitivity.
You F; Luan H; Sun D; Cui T; Ding P; Tang H; Sun D
DNA Cell Biol; 2019 Feb; 38(2):198-207. PubMed ID: 30570350
[TBL] [Abstract][Full Text] [Related]
11. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
13. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer.
He H; Tian W; Chen H; Jiang K
Tumour Biol; 2016 Feb; 37(2):1599-607. PubMed ID: 26298722
[TBL] [Abstract][Full Text] [Related]
14. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ.
Yang W; Yang X; Wang X; Gu J; Zhou D; Wang Y; Yin B; Guo J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):4921-4932. PubMed ID: 31245927
[TBL] [Abstract][Full Text] [Related]
15. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.
Dong Z; Zhong Z; Yang L; Wang S; Gong Z
Cancer Lett; 2014 Feb; 343(2):249-57. PubMed ID: 24099915
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
18. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
Xu X; Lv YG; Yan CY; Yi J; Ling R
Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
[TBL] [Abstract][Full Text] [Related]
19. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
20. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]